Early cancer detection is a key determinant of patient survival, but scientists struggle to identify reliable biomarkers and diagnostic tools. Researchers recently discovered cancer-specific glycosylation signatures that promote tumor progression. Because protein glycosylation controls cellular behaviors such as cell adhesion and migration, altered glycosylation states render cancer cells more invasive. In this webinar, brought to you by Vector Laboratories, Karen Abbott and Susan Bellis discuss how cancer cells modify glycosylation pathways to survive, and how to target tumor-specific glycans for early cancer detection, prognosis, and therapeutic development.

Topics covered:

• Tools and technologies to detect glycan biomarkers
• How cancer-induced receptor glycosylation activates tumorigenic pathways
• The therapeutic potential of tumor-selective glycans